CYP1A2 164 A→C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2289-2295

  Sæbø, Mona ^a   Skjelbred, Camilla F ^a,b   Li, Karin Brekke ^a   Lothe, Inger Marie Bowitz ^c   Hagen, Per Chr ^a   Johnsen, Egil ^d   Tveit, Kjell M ^c   Kure, Elin H ^a,c  

^a UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

^b TELEMARK HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colorectal adenomas; Colorectal carcinomas; CYP1A2 164 A C polymorphism; Red meat; Smoking

Indexed keywords

CYTOCHROME P450 1A2; CYP1A2 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CIGARETTE SMOKING; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; FOOD INTAKE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RED MEAT; RISK ASSESSMENT; ADENOMA; CASE CONTROL STUDY; COLORECTAL TUMOR; DIET; ENZYMOLOGY; GENETICS; MEAT; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADENOMA; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOCHROME P-450 CYP1A2; DIET; FEMALE; GENOTYPE; HUMANS; MALE; MEAT; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING;

EID: 48849115873     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8): S4-66, 2001.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE , Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
3. Bond JH: Clinical evidence for the adenoma carcinoma sequence and the management of patients with colorectal adenomas. Semin Gastrointest Dis 11: 176-184, 2000.
4. Giovannucci E: An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 10: 725-731, 2001.
5. Almendingen K, Hofstad B, Trygg K, Hoff G, Hussain A and Vatn MH: Smoking and colorectal adenomas: a case-control study. Eur J Cancer Prev 9: 193-203, 2000.
6. Heavey PM, McKenna D and Rowland IR: Colorectal cancer and the relationship between genes and the environment. Nutr Cancer 48: 124-141, 2004.
7. Potter JD: Colorectal cancer: molecules and populations. J Natl Cancer Inst 91: 916-932, 1999.
8. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A and Willett WC: Intake of fat meat and fiber in relation to risk of colon cancer in men. Cancer Res 54: 2390-2397, 1994.
9. Manabe S, Tohyama K, Wada O and Aramaki T: Detection of a carcinogen 2-amino-1-methyl-6-phenylimidazo[45-b]pyridine (PhIP) in cigarette smoke condensate. Carcinogenesis 12: 1945-1947, 1991.
10. Wogan GN, Hecht SS and Felton JS: Environmental and chemical carcinogenesis. Semin Cancer Biol 14: 473-486, 2004.
11. Yamasaki E and Ames BN: Concentration of mutagens from urine by absorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. Proc Natl Acad Sci USA 74: 3555-3559, 1977.
12. Kune GA, Kune S, Vitetta L and Watson LF: Smoking and colorectal cancer risk: data from the Melbourne Colorectal Cancer Study and brief review of literature. Int J Cancer 50: 369-372, 1992.
13. International Agency for Research on Cancer: Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum Vol 83, IARC, Lyon, France, pp. 1-1438, 2004.
14. Koide A, Fuwa K, Furukawa F, Hirose M, Nishikawa A and Mori Y: Effect of cigarette smoke on the mutagenic activation of environmental carcinogens by rodent liver. Mutat Res 428: 165-176, 1999.
15. Ishibe N, Sinha R, Hein D, Kulldorff M, Strickland P, Fretland AJ, Chow WH, Kadlubar FF, Lang NP and Rothman N: Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 12: 145-150, 2002.
16. Guengerich FP: Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett 70: 133-138, 1994.
17. Eaton DL, Gallagher EP, Bammler TK and Kunze KL: Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5: 259-274, 1995:
18. Boobis AR, Lynch AM, Murray S, de la Torre R, Solans A, Farre M, Segura J, Gooderham NJ and Davies DS: CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 54: 89-94, 1994.
19. Kalow W and Tang BK: Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50: 508-519, 1991.
20. Aitchison KJ, Gonzalez FJ, Quattrochi LC, Sapone A, Zhao JH, Zaher H, Elizondo G, Bryant C, Munro J, Collier DA, Makoffa and Kerwin RW: Identification of novel polymorphisms in the 5' flanking region of CYP1A2 characterization of interethnic variability and investigation of their functional significance. Pharmacogenetics 10: 695-704, 2000.
21. Landi MT, Sinha R, Lang NP and Kadlubar FF: Human cytochrome P4501A2. IARC Sci Publ 148: 173-195, 1999.
22. Ou-Yang DS, Huang SL, Wang W, Xie HG, Xu ZH, Shu Y and Zhou HH: Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 49: 145-151, 2000.
23. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF and Kadlubar FF: Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2: 116-127, 1992.
24. Schrenk D, Brockmeier D, Morike K, Bock KW and Eichelbaum M: A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 53: 361-367, 1998.
25. Kitada M, Taneda M, Ohta K, Nagashima K, Itahashi K and Kamataki T: Metabolic activation of aflatoxin B1 and 2-amino-3-methylimidazo[45-f]-quinoline by human adult and fetal livers. Cancer Res 50: 2641-2645, 1990.
26. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR and Gooderham NJ: Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55: 68-76, 2003.
27. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M and Kamataki T: Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 125: 803-808, 1999.
28. Sachse C, Brockmoller J, Bauer S and Roots I: Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47: 445-449, 1999.
29. MacLeod S, Sinha R, Kadlubar FF and Lang NP: Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat Res 376: 135-142, 1997.
30. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, Seifried A, Custer LJ, Chang W, Lum-Jones A and Donlon T: Combined effects of well-done red meat, smoking and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1259-1266, 2001.
31. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M and Kadlubar FF: Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 3: 675-682, 1994.
32. Moonen HJ, Moonen EJ, Maas L Dallinga JW, Kleinjans JC and de Kok TM: CYP1A2 and NAT2 genotype/phenotype relations and urinary excretion of 2-amino-1-methyl-6-phenylimidazo[45-b]pyridine (PhIP) in a human dietary intervention study. Food Chem Toxicol 42: 869-878, 2004.
33. Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK, Shin DW, Pie JE, Woo ZH and Kang JH: Effects of genetic polymorphisms of MDR1 FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 97: 774-779, 2006.
34. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ and Hoff G: The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 38: 635-642, 2003.
35. Hansen R, Saebo M, Skjelbred CF, Nexo BA, Hagen PC, Bock G, Bowitz Lothe IM, Johnson E, Aase S, Hansteen IL, Vogel U and Kure EH: GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett 229: 85-91, 2005.
36. http://www.clinicaltrials.gov
37. Winawer SJ and Zauber AG: The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 12: 1-9 v, 2002.
38. Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
39. Christiansen L, Bygum A, Jensen A, Thomsen K, Brandrup F, Horder M and Petersen NE: Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 107: 612-614, 2000.
40. Todesco L, Torok M, Krahenbuhl S and Wenk M: Determination of -3858G->A and -164C->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G->A mutation between Caucasians and Asians. Eur J Clin Pharmacol 59: 343-346, 2003.
41. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT and Wolf CR: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839-1849, 2002.
42. Gaard M, Tretli S and Loken EB: Dietary factors and risk of colon cancer: a prospective study of 50535 young Norwegian men and women. Eur J Cancer Prev 5: 445-454, 1996.
43. Yoon H, Benamouzig R, Little J, Francois-Collange M and Tome D: Systematic review of epidemiological studies on meat dairy products and egg consumption and risk of colorectal adenomas. Eur J Cancer Prev 9: 151-164, 2000.
44. Kampman E, Slattery ML, Bigler J, Leppert M, Samowitz W, Caan BJ and Potter JD: Meat consumption genetic susceptibility and colon cancer risk: a United States multicenter case-control study. Cancer Epidemiol Biomarkers Prev 8: 15-24, 1999.
45. Sandhu MS, White IR and McPherson K: Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev 10: 439-446, 2001.
46. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N and Goebell H: Colorectal adenomas and diet: a case-control study. Colorectal Adenoma Study Group. Dig Dis Sci 46: 86-95, 2001.
47. Norat T and Riboli E: Meat consumption and colorectal cancer: a review of epidemiologic evidence. Nutr Rev 59: 37-47, 2001.
48. Augustsson K, Skog K, Jagerstad M, Dickman PW and Steineck G: Dietary heterocyclic amines and cancer of the colon rectum bladder and kidney: a population-based study. Lancet 353: 703-707, 1999.
49. Butler LM, Sinha R and Millikan RC: Heterocyclic amines meat intake and association with colon cancer in a population-based study. Am J Epidemiol 157: 434-445, 2003.
50. Sinha R, Rothman N, Brown ED, Salmon CP, Knize MG, Swanson CA, Rossi SC, Mark SD, Levander OA and Felton JS: High concentrations of the carcinogen 2-amino-1-methyl-6-phenylimidazo-[45-b]pyridine (PhIP) occur in chicken but are dependent on the cooking method. Cancer Res 55: 4516-4519, 1995.
51. Kiss I, Orsos Z, Gombos K, Bogner B, Csejtei A, Tibold A, Varga Z, Pazsit E, Magda I, Zolyomi A and Ember I: Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res 27: 2931-2937, 2007.
52. Moonen H, Engels L, Kleinjans J and Kok T: The CYP1A2-164A->C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans. Cancer Lett 229: 25-31, 2005.
53. Kootstra-Ros JE, Smallegoor W and van der Weide J: The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 42: 216-219, 2005.
54. van der Weide J, Steijns LS and van Weelden MJ: The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13: 169-172, 2003.
55. Nordmark A, Lundgren S, Ask B, Granath F and Rane A: The effect of the CYP1A2* 1F mutation on CYP1 A2 inducibility in pregnant women. Br J Clin Pharmacol 54: 504-510, 2002.
56. Bond JH: Polyp guideline: diagnosis treatment and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 95: 3053-3063, 2000.
57. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H and Chejfec G: Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343: 162-168, 2000.